Non-B HIV type 1 subtypes: Replicative capacity and response to antiretroviral therapy

AIDS Research and Human Retroviruses

Volumn 20, Issue 8, 2004, Pages 816-818

  Nicastri, Emanuele ^a   Sarmati, Loredana ^b   D'Ettorre, Gabriella ^c   Parisi, Saverio G ^d   Palmisano, Lucia ^e   Montano, Marco ^b   Buonomini, Anna Rita ^b   Galluzzo, Clementina ^e   Vullo, Vincenzo ^c   Concia, Ercole ^d   Vella, Stefano ^e   Andreoni, Massimo ^b  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; NELFINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LYMPHOCYTE COUNT; MALE; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TYPING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV-1; HUMANS; MALE; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 4344689447     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/0889222041725271     Document Type: Article

References (8)

1. Perrin L, Kaiser L, and Yerly S: Travel and the spread of HIV-1 genetic variants. Lancet Infect Dis 2003;3:22-27.
2. Alaeus A, Lidman K, Bjorkman A, Giesecke J, and Albert J: Similar rate of disease progression among individuals infected with HIV-1 genetic subtypes A-D. AIDS 1999;13:901-907.
3. Pillay D, Walker AS, Gibb DM, de Rossi A, Kaye S, Ait-Khaled M, Munoz-Fernandez M, and Babiker A: Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. J Infect Dis 2002;186:617-625.
4. Nicastri E, Sarmati L, d'Ettorre G, Palmisano L, Parisi SG, Uccella I, Rianda A, Concia E, Vullo V, Vella S, and Andreoni M: Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. J Med Virol 2003;69:1-6.
5. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, and Shafer RW: Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 2003;31:298-303.
6. Grossman Z, Vardinon N, Chemtob D, Alkan ML, Bentwich Z, Burke M, Gottesman G, Istomin V, Levi I, Maayan S, Shahar E, Schapiro JM, and the Israel Multi-Center Study Group: Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B. AIDS 2001;15:1453-1460.
7. Alexander CS, Montessori V, Wynhoven B, Dong W, Chan K, O'Shaughnessy MV, Mo T, Piaseczny M, Montane JS, and Harrigan PR: Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia. Antiviral Ther 2002;7:31-35.
8. Kantor R, Katzenstein D, Gonzales M, Sirivichayakul S, Cane P, Pillay C, Snoeck J, Grossman Z, Vandamme A-M, Morris L, Pillay D, Phanuphak P, Schapiro JM, and Shafer RW: Influence of subtype and treatment on genetic profiles of HIV-1 reverse transcriptase and protease: Do they act independently in predicting position-specific mutation probabilities in non-subtype B sequences? Antiviral Ther 2002:7:S142 (Abstract 171).